Your browser doesn't support javascript.
loading
Assessing meaningful change in the Asthma Impairment and Risk Questionnaire.
McCann, William; Murphy, Kevin R; Zeiger, Robert S; Beuther, David A; Wise, Robert A; Reibman, Joan; George, Maureen; Gilbert, Ileen; Eudicone, James M; Gandhi, Hitesh N; Cutts, Katelyn; Coyne, Karin S; Chipps, Bradley.
Affiliation
  • McCann W; Allergy Partners, Asheville, North Carolina. Electronic address: bmccann@allergypartners.com.
  • Murphy KR; Division of Allergy, Asthma and Immunology, Boys Town National Research Hospital, Boys Town, Nebraska.
  • Zeiger RS; Departments of Allergy and Research and Evaluation, Kaiser Permanente Southern California, San Diego and Pasadena, California.
  • Beuther DA; Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, Colorado.
  • Wise RA; Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Reibman J; Department of Medicine, New York University (NYU) Grossman School of Medicine, New York, New York.
  • George M; Department of Nursing, Columbia University School of Nursing, New York, New York.
  • Gilbert I; BioPharmaceuticals Medical, AstraZeneca, Wilmington, Delaware.
  • Eudicone JM; BioPharmaceuticals Medical, AstraZeneca, Wilmington, Delaware.
  • Gandhi HN; BioPharmaceuticals Medical, AstraZeneca, Wilmington, Delaware.
  • Cutts K; Patient-Centered Research, Evidera, Bethesda, Maryland.
  • Coyne KS; Patient-Centered Research, Evidera, Bethesda, Maryland.
  • Chipps B; Capital Allergy and Respiratory Disease Center, Sacramento, California.
Ann Allergy Asthma Immunol ; 133(2): 152-158, 2024 Aug.
Article in En | MEDLINE | ID: mdl-38369256
ABSTRACT

BACKGROUND:

The Asthma Impairment and Risk Questionnaire (AIRQ) is a 10-item, yes/no, equally weighted control tool. Lower scores indicate better control. Moreover, 7 impairment items reflect previous 2-week symptoms, and 3 risk items assess previous 12-month exacerbations. The Follow-up AIRQ for use between annual assessments has a 3-month recall period for exacerbation items.

OBJECTIVE:

To evaluate the responsiveness of the AIRQ over time and identify a minimal important difference (MID).

METHODS:

The AIRQ longitudinal study data were analyzed from patients with asthma aged 12 years and older. Anchor-based methods assessed differences in AIRQ scores relative to Patient Global Impression of Change, the accepted MIDs for St. George's Respiratory Questionnaire and Asthma Control Test, and exacerbation occurrence over 12 months. Baseline and 12-month data reflected 12-month recall AIRQ scores; Follow-up AIRQ scores were used for 3-, 6-, and 9-month analyses.

RESULTS:

A total of 1070 patients were included. The Patient Global Impression of Change rating of "much improved" was associated with AIRQ mean score changes from baseline to months 3, 6, 9, and 12 of -2.0, -1.9, -1.9, and -1.8, respectively. The mean AIRQ score change among patients who met the St. George's Respiratory Questionnaire MID (≥4-point decrease) was -1.8 at 6 and 12 months. The AIRQ mean scores decreased from baseline by -2.2 to -2.5 points at months 3, 6, 9, and 12 for patients who met the Asthma Control Test MID (≥ 3-point increase). A 2-point higher baseline AIRQ score was associated with a 1.7 odds ratio of 12-month exacerbation occurrence (95% CI, 1.53-1.89).

CONCLUSION:

A change score of 2 is recommended as the AIRQ MID.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Asthma Limits: Adolescent / Adult / Aged / Child / Female / Humans / Male / Middle aged Language: En Journal: Ann Allergy Asthma Immunol Journal subject: ALERGIA E IMUNOLOGIA Year: 2024 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Asthma Limits: Adolescent / Adult / Aged / Child / Female / Humans / Male / Middle aged Language: En Journal: Ann Allergy Asthma Immunol Journal subject: ALERGIA E IMUNOLOGIA Year: 2024 Document type: Article